Three analysts set AUD 4.37 target: 4Dmedical stock sits 17.16 percent below it

Published on 10/20/2026 at 20:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

4DMedical's AGM is set for October 28, 2026. 4Dmedical stock costs EUR 2.35 on October 20, 2026 versus AUD 3.73 on the ASX.

Analyst target and reporting date

Three analysts set an average AUD 4.37 target in September 2026, 17.16 percent above the ASX quote of AUD 3.73.
4DMedical's annual general meeting is scheduled for October 28, 2026.
4Dmedical stock costs EUR 2.35 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST.
The company has a market capitalization of AUD 2.2 billion and a 52-week range of AUD 1.40 to AUD 7.55.

4Dmedical, AU0000095416, Illustration mit AI erstellt.

4DMedical (ISIN AU0000095416) faces a valuation test as three analysts set an average AUD 4.37 target, while the ASX quote stood at AUD 3.73 on October 20, 2026. Simply Wall St reported that analysts had reset the target from AUD 4.97 to AUD 4.37. The new target is 17.16 percent above the ASX quote. The stock was trading at EUR 2.35 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST.

Target cut sharpens the valuation debate

The AUD 0.60 reduction represents a 12.07 percent cut from the earlier AUD 4.97 target. The updated average still stands above the ASX price, but the distance is smaller than the previous valuation implied.

4DMedical describes itself as an ASX-listed medical technology company focused on diagnostic imaging for respiratory conditions. Its proprietary XV Technology and Imbio Technology are designed to support lung-function analysis without contrast agents.

Stock remains below its yearly high

The ASX quote was AUD 3.73 on October 20, 2026, against a 52-week range of AUD 1.40 to AUD 7.55. That places the quote 50.60 percent below the yearly high and 166.43 percent above the yearly low. The range gives the analyst target a middle position between the recent extreme levels.

4DMedical's market capitalization was AUD 2.2 billion on October 20, 2026. The finance technology company operates in the medical technology industry, with its Australian listing identified as ASX:4DX.

Annual meeting sets the next date

The next scheduled corporate date is 4DMedical's annual general meeting on October 28, 2026, as listed by Simply Wall St. The meeting comes after the September target revision and gives investors a dated point for reviewing execution, commercialization and capital allocation.

What the figures mean for the stock

The market picture combines a EUR 2.35 Lang & Schwarz indication with an AUD 3.73 ASX quote and an AUD 4.37 analyst average. Those currencies cannot be combined into one return calculation, but the Australian figures show that the target remains 17.16 percent above the home-market quote.

Price and investor dates

4Dmedical stock was trading at EUR 2.35 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of 4Dmedical stock.